Press Release: Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development

More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 // -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics. Biotechs are launching pre-configured and pre-validated Veeva Basics applications in weeks, adding systems that can scale as they move from startup to commercialization. Veeva Basics delivers unified, end-to-end applications for clinical, regulatory, quality, medical, and commercial, enabling high-growth companies to speed innovation while saving time, effort, and cost. "As a growing company with under 40 employees, we're focused on developing science fast to deliver antibody-drug conjugates (ADCs) that target difficult-to-treat cancers," said Bryan Ball, chief technology operations officer at Whitehawk Therapeutics. "Our partnership with Veeva helped us replace paper processes with industry-leading solutions without an IT team or complex customizations. Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance." Biotechs are leveraging Veeva Basic